MeSH D020388 - duchenne muscular dystrophy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals | VAMOROLONE | Agamree | 2029-05-28 | 2023-10-26 | $1.174 M | Y2024 |
| Nippon Shinyaku | Viltolarsen | Viltepso | 2031-08-31 | 2020-08-12 | ||
| PTC Therapeutics | Deflazacort | Emflaza | 2017-02-09 | $258 M | Q2/23-Q1/24 | |
| Ataluren | Translarna | 2014-07-31 | $344.3 M | Q2/23-Q1/24 | ||
| Sarepta Therapeutics | Casimersen | Amondys | 2025-06-28 | 2021-02-25 | $33.784 M | Y2021 |
| Eteplirsen | Exondys | 2025-06-28 | 2016-09-19 | $447.046 M | Q3/20-Q3/21 | |
| Golodirsen | Vyondys | 2025-06-28 | 2019-12-12 | $74.275 M | Q3/20-Q3/21 |
Clinical Trials
Historical Success Rate
Phase 1
59%19/32
Phase 2
63%15/24
Phase 3
45%13/29
Approved: 7Overall Success rate: 17%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use